A 45-year-old man had a prolonged vaso-vagal attack witnessed whilst attending a hypertension clinic. He had been fully investigated 12 months earlier when he presented with hypertension (blood pressure 160 mm Hg systolic, 112 mm Hg diastolic despite treatment with atenolol 100 mg daily). No underlying cause for his hypertension was found. Renal function was normal and echocardiography revealed borderline left ventricular hypertrophy. Blood pressure was poorly controlled on an angiotensin receptor antagonist (candesartan 16 mg daily) and 2 months prior to the current presentation, bendroflumethiazide 2.5 mg daily had been added.
Prior to his current visit he had been unwell with a mild, flu-like illness. In the clinic he suddenly collapsed, hypotensive (blood pressure circa 70 mm Hg systolic, 30 mm Hg diastolic) with an extreme bradycardia (40 beats per minute). He slowly recovered over a period of about 5 min, only to experience a further vaso-vagal attack 10 min later. Recovery was slow and he remained hypotensive (blood pressure systolic 100 mm Hg, diastolic 65 mm Hg) and was admitted for observation overnight. All subsequent investigations including cardiac enzymes and electrocardiograms (ECG) were normal.
Six months following this episode a second hypertensive patient, a male aged 37, also collapsed in the clinic with a vasovagal attack from which he slowly recovered, requiring observation for the following 3 h because of significant hypotension (systolic blood pressure circa 100 mm Hg). ECG was normal. This patient also had uncomplicated essential hypertension and had been stabilised on treatment with the angiotension receptor antagonist, candesartan 8 mg daily. Of note he had also complained of a mild virus-type illness for the previous 24 h.
This second episode prompted the recall of an account given by a third patient, the wife of a physician, in whose consulting room she had collapsed 2 years previously. The event was witnessed by two physicians who subsequently reported that the unusual feature of the presumed vaso-vagal episode was the prolonged period of recovery from hypotension and bradycardia. This patient was also taking the angiotensin receptor antagonist, candesartan 16 mg daily.
Full investigations had formally been carried out in all three patients and no clinical signs nor biochemical evidence of hypoadrenalism was present.
The common features relating to all three patients were treatment of essential hypertension with an angiotension receptor antagonist and vaso-vagal episodes characterised by slow recovery from hypotension and bradycardia. In retrospect the administration of atropine would have accelerated heart rate in the presence of vaguely-induced bradycardia, however in neither case in the clinic was there prolonged haemodynamic instability, which would have required resuscitative measures including atropine.
We are unaware that this association has been reported hitherto but we believe it may be explained by sensitisation of the Bezold-Jarisch reflex 1, 2 conditioned by the withdrawal of the influence of angiotension II. Angiotensin II may exert its effect via a central mechanism, which serves to ameliorate the vagallyinduced bradycardia and withdrawal of sympathetic tone consequent upon activation of the afferent pathways of this reflex. 3 The Bezold-Jarisch reflex is initiated by stimulation of chemosensitive and mechanosensitive receptors in the wall of the left ventricle: receptors which respond to a variety of stimuli including reduction in central blood volume, coronary occlusion, hypoxia and certain chemical substances. 3 Afferent pathways consist of unmyelinated or C-fibre afferents which are carried by the vagus nerve to cardiovascular regulatory nuclei in the brain stem (nucleus tractus solitarius, dorsal motor nucleus of the vagus). The efferent pathways involve vagally-induced bradycardia and withdrawal of sympathetic tone.
Activation of the pathway causes vago-vagal syncopy and may account for the exertional syncopy of aortic stenosis, the haemodynamic response to inferposterior myocardial infarction, hypovolaemic shock and the syncopy associated with passive tilting.
The reflex originally described by von Bezold and Hirt 1 and later Jarisch 2 may be triggered by or ameliorated by various drugs or hormones.
Veratrum alkaloids, bradykinin, atrial natriuretic peptides, prostanoids and nitrovasodilators, for example, may trigger the reflex. By way of contrast, angiotensin II may attenuate the hypotensive and vagal components of the BezoldJarisch reflex. 3 Profound hypo-Journal of Human Hypertension tension and bradycardia has been reported in man with infusions of renin inhibitors and attributed to an exaggeration of the Bezold-Jarisch reflex. 4 A similar mechanism may contribute to the hypotensive response to the first dose of an angiotensin converting enzyme (ACE) inhibitor when used in the treatment of heart failure. In this situation potentiation of bradykinin may stimulate the chemosensitive endings in the heart contributing to reflex activation. Hypotension is also a significant problem during anaesthesia in patients receiving ACE inhibitors. Is a similar problem seen with angiotensin receptor antagonists?
We therefore propose that in the three cases reported here blockade of angiotensin (AT1) receptors by the antagonist candesartan removes the modulating effects of angiotensin II on the Bezold-Jarisch reflex and in circumstances when a vaso-vagal reaction is likely to occur, there is sensitisation of the pathway and exaggeration of the withdrawal of sympathetic tone, vasodilatation and profound bradycardia. We propose to test this hypothesis by further investigation including autonomic function studies prior to and following the administration of an angiotensin receptor antagonist.
Angiotensin receptor antagonists are increasingly used in the treatment of hypertension where they are well tolerated. Drug and doserelated side effects have not been identified in placebo controlled clinical trials to date. Nevertheless post marketing surveillance studies report 'dizziness' as one of the most common symptoms reported by patients taking these drugs. 5 The identification of an uncommon side effect of a drug requires clinical vigilance and clinicians should be aware of this possible adverse reaction to angiotensin receptor blocking drugs, particularly in view of their increasing use in the management of hypertension and heart failure. 
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